Study of Diroximel Fumarate in the Real-World Setting

TerminatedOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

April 14, 2023

Study Completion Date

April 14, 2023

Conditions
Relapsing Forms of MS
Interventions
DRUG

Diroximel Fumarate

As described in the arm.

Trial Locations (18)

14202

Jacobs School of Medicine and Biomedical Sciences, Buffalo

17822

Geisinger Medical Center, Danville

20007

MedStar Georgetown University Hospital, Washington D.C.

23601

Riverside Neurology Specialists, Newport News

27405

Cone Health, Greensboro

37922

Hope Neurology, Knoxville

40207

Norton Neuroscience Institute, Louisville

48071

Glendale Neurological Associates, PC, Farmington

48867

Memorial Healthcare, Owosso

64111

St. Luke's Neurology, Kansas City

77030

UTHealth Neurosciences Texas Medical Center II, Houston

90048

Regina Berkovich MD Phd Inc, West Hollywood

97225

Providence Brain and Spine Institute, Portland

99204

Providence Medical Research Center, Spokane

02215

Beth Israel Deaconess Medical Center, Boston

07728

CentraState Healthcare System - Linda Cardinale MS Center, Freehold

07039

MS Center at St Barnabas, Livingston

07753

Multiple Sclerosis Center JSUMC, Neptune City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY